Last reviewed · How we verify
B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma
It's the first-in-human study of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection (B001). The main purpose of this study is to explore the safety and tolerance of B001 for patients with CD20 positive B-cell non Hodgkin's lymphoma. It will also explore the PK/PD manner and ORR in this study.
Details
| Lead sponsor | Shanghai Pharmaceuticals Holding Co., Ltd |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 30 |
| Start date | Thu Mar 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Feb 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- CD20 Positive B Cell Non-Hodgkin's Lymphoma
Interventions
- B001
Countries
China